Drug Trial Radar · NCT02466490
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Apr 2013
Primary completion
Feb 2014
Study completion Feb 2014
Sponsor
- Lead sponsor
- Stendhal Americas, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fimasartan (FMS) is an AT1 receptor antagonist indicated for once a day administration, currently approved for the treatment of essential hypertension in Corea and Mexico. As the safety and efficacy of FMS was initially demonstrated in Korea only, it was necessary to address the potential for ethnic factors to have an effect on the drug´s efficacy and safety in the Mexican population. To address this need, a cohort of 272 Mexican subjects with grades 1-2 essential hypertension were sequentially treated on a treat to target basis (target: sitting Diastolic Blood Pressure (sDBP) \<90 mmHg) with 60 mg FMS once a day (8 weeks), either 120 mg FMS or 60 mg FMS+12.5 mg HCTZ once a day (randomized 4 week treatment period) and 120 mg FMS once a day (during 12 weeks) for a total treatment period of 24 weeks.
Conditions
- Hypertension, Essential
Interventions
FimasartanDrug
Fimasartan tablets
Fimasartan; HydrochlorothiazideDrug
Fimasartan plus hydrochlorothiazide fixed dose combination tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood Pressure Change From BaselineTime frame: Baseline to Treatment Week 8
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Hospital de Jesús IAP
México, D.f., Mexico
Hospital General de Ticomán
México, D.f., Mexico
Centro Médico Exel
Tijuana, Estado de Baja California, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico
Unidad de Investigación Clínica Cardiometabólica de Occidente
Guadalajara, Jalisco, Mexico
Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara
Guadalajara, Jalisco, Mexico
Icle S.C.
Guadalajara, Jalisco, Mexico
Núcleo Médico La Paz
Guadalajara, Jalisco, Mexico
Hospital Dr. Ángel Leaño
Zapopan, Jalisco, Mexico
Instituto Jalisciense de Investigación en Diabetes y Obesidad S. C.
Guadalajara, Jalsico, Mexico
Cardiolink Clintrials
Monterrey, Nuevo León, Mexico
Centro de Estudios Clínicos y Especialidades Médicas
Monterrey, Nuevo León, Mexico
Hospital Dr. Ignacio Morones Prieto
San Luis Potosí City, San Luis Potosí, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.